



11 October 2018

## ASX Announcement

### Penthrox is approved in Saudi Arabia

Medical Developments International Limited (ASX:MVP), announce today that Penthrox® has been granted Marketing Authorisation in the Kingdom of Saudi Arabia (KSA). The Marketing Authorisation issued by the Saudi Food and Drug Administration (SFDA), is for Penthrox® to be used for Emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.

Mr. John Sharman, Chief Executive Officer said: "This is a very exciting day for MVP. The Kingdom of Saudi Arabia is a key market for Penthrox in the Middle East and we have been working with our partner, Yahmaa Medical Company since 2014 to get Penthrox approved. We expect the granting of this Marketing Authorisation will have positive ramifications for the rest of this region and be a catalyst for a number of other country approvals in the Middle East."

Mr. Sharman said, "The administration of opioids to treat moderate to severe pain is extremely rare and under strict government control in Saudi Arabia and the Middle East generally. Compared to "western world" standards, patients in the Middle East are often undertreated for pain. We understand less than 10,000 patients receive an opioid for the emergency relief of pain each year. There is a significant opportunity to improve the wellbeing of patients suffering moderate to severe pain through the use of Penthrox."

Dr Allam Al-Barazi, Director of Yahmaa Medical Company said: "There is more than 16.7 million medical emergency visits to Saudi hospitals, medical centers and day clinics (Ref.: 2017 Annual Statistical Book/Saudi MOH) and more than 5.5 million of these patients receive non-opioid pain relief such as Voltaren (diclofenac) and paracetamol."

Dr Al-Barazi said; "Yahmaa believe a non-opioid, non-addictive, non-invasive, fast-acting, treatment option like Penthrox is necessary in the Kingdom of Saudi Arabia. Penthrox is safe and effective and easy to use. We are confident Penthrox will be a great success in pain management in patients suffering moderate to severe pain within the Kingdom of Saudi Arabia."

Enquiries:

David Williams  
Chairman  
Medical Developments International Ltd  
+61 (0) 414 383 593

John Sharman  
Chief Executive Officer  
Medical Developments International Ltd  
+61 (3) 9547 1888



## **About Pentrox®**

Pentrox® (methoxyflurane) is the only small, lightweight, handheld, fast-acting, non-opioid inhaled analgesic that is self-administered under the supervision of the treating healthcare practitioner, indicated for the short-term relief of moderate to severe pain, associated with trauma or interventional medical procedures, in conscious patients. Pentrox has been used safely and effectively for more than 30 years in Australia with more than 5.0 million units sold. Since 2016, Pentrox has been approved for sale in 33 countries. Pentrox® provides rapid, effective pain relief within 5 minutes, with no need for needles. Pentrox® allows patients to control their own pain relief by moderating the amount of Pentrox® inhaled.

## **About Medical Developments International Ltd**

MDI is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MDI is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox® a fast-acting trauma & pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defense Forces, sports medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MDI is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

## **About Yahmaa Medical Company**

Yahmaa is one of Saudi Arabia's leading and fastest growing pharmaceutical companies and has more than 33 partnerships with international companies for the importation, marketing and distribution of pharmaceuticals in Saudi Arabia. Yahmaa was formed with a mission to serve all aspects of the Saudi healthcare industry and its range of products include vaccines, CNS, CVS, pain and biological products. The company benchmarks itself as one of the leading providers of pharmaceuticals and medical supplies within the government, semi-government and private sectors. Yahmaa reached this milestone by adopting a strong focused approach towards clients and partners and by forging successful partnerships with leading global pharmaceutical and medical supply companies, Yahmaa continues its stride forward and introduces innovative solutions and products into Saudi Arabia.